Alethia BioTherapeutics Inc.

Alethia BioTherapeutics Inc.

August 03, 2005 08:30 ET

Alethia BioTherapeutics Inc. Appoints Mr. Yves Cornellier as President and Chief Executive Officer

MONTREAL, QUEBEC--(CCNMatthews - Aug. 3, 2005) - Alethia BioTherapeutics, Inc., a biotechnology with innovative approaches for the treatment of cancer and related diseases, is pleased to announce the appointment of Mr. Yves Cornellier as President and CEO and member of its board of directors.

"We are delighted to have Yves join Alethia as Chief Executive Officer at this stage of evolution of our company. Yves' broad experience in the pharmaceutical and biotechnology industry will be invaluable as we move our novel therapies for cancer towards the clinic and shape the organization's ambitious future" commented Dr. Mario Filion, founder of Alethia and its Chief Scientific Officer.

"I am excited about the opportunity which Alethia represents. Alethia has assembled a unique integrated target discovery and validation platform and has rapidly developed a rich portfolio of targets for development of highly specific therapeutics. I look forward to contributing to the growth and success of the company by putting in place the capabilities that will aloow the evolution of the company from a pure drug discovery to a full product development organization" said Yves Cornellier.

About Yves Cornellier

Mr. Cornellier is a veteran marketing and sales professional with more than 25 years in the healthcare industry and extensive experience negotiating licensing and collaboration agreements with large pharmaceutical companies, biotechnology companies and institutions. Prior to joining Alethia, Yves was Senior Vice President, Business Development for LAB International Inc. since October 2003, subsequent to the acquisition of Seyvika Pharmaceuticals for which he was the founder. Prior, he held the position of Vice-President, Business Development and Commercialization at Theratechnologies, and also held the position of Director of Business Development and Senior Marketing Manager, Pharmaceuticals Product Division, for Abbott Laboratories Ltd. He also had the opportunity to work for Glaxo Canada and Miles Laboratories Canada in management positions of increasing responsibility including sales management, marketing, business unit management and strategic development. Mr. Cornellier is also a member of the Board of Directors of Diagnocure Inc. (TSX:CUR), a publicly traded company on the Toronto Stock Exchange.

About Alethia BioTherapeutics

Established in 2002, Alethia BioTherapeutics is Montreal-based biotechnology company engaged in the discovery and development of therapeutics for the treatment of cancer and cancer-associated complications. Alethia applies its proprietary discovery platform for identification and validation of therapeutic targets in cancer-induced bone loss, ovarian cancer and breast cancer.

Contact Information